Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CFLT Stock Forecast 2026-2027
$30.99
Current Price
$11.13B
Market Cap
Buy 0
Hold 11
Sell 0
Wall St Analyst Ratings
Distance to CFLT Price Targets
+0.0%
To High Target of $31.00
+0.0%
To Median Target of $31.00
+0.0%
To Low Target of $31.00
CFLT Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+26.5%
1 Year Change
+2.5%
Year-to-Date Change
0.0%
From 52W High of $31.00
+98.1%
From 52W Low of $15.64
📊 TOP ANALYST CALLS
Did CFLT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Confluent is one of their latest high-conviction picks.
Latest CFLT Stock Price Targets & Analyst Predictions
Based on our analysis of 43 Wall Street analysts, CFLT has a neutral consensus with a median price target of $31.00 (ranging from $31.00 to $31.00). The overall analyst rating is Buy (6.3/10). Currently trading at $30.99, the median forecast implies a 0.0% upside. This outlook is supported by 0 Buy, 11 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Peter Weed at Bernstein, projecting a 0.0% upside. Conversely, the most conservative target is provided by Peter Weed at Bernstein, suggesting a 0.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CFLT Analyst Ratings
0
Buy
11
Hold
0
Sell
CFLT Price Target Range
Low
$31.00
Average
$31.00
High
$31.00
Current: $30.99
Latest CFLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CFLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 23, 2026 | Bernstein | Peter Weed | Market Perform | Downgrade | $31.00 |
| Jan 9, 2026 | Citizens | Patrick Walravens | Market Perform | Downgrade | $N/A |
| Dec 10, 2025 | Guggenheim | Howard Ma | Neutral | Downgrade | $N/A |
| Dec 9, 2025 | Baird | William Power | Neutral | Maintains | $31.00 |
| Dec 9, 2025 | Oppenheimer | Ittai Kidron | Perform | Downgrade | $N/A |
| Dec 9, 2025 | Needham | Mike Cikos | Hold | Downgrade | $N/A |
| Dec 9, 2025 | Canaccord Genuity | Kingsley Crane | Hold | Downgrade | $31.00 |
| Dec 9, 2025 | UBS | Radi Sultan | Neutral | Downgrade | $31.00 |
| Dec 9, 2025 | Raymond James | Mark Cash | Market Perform | Downgrade | $N/A |
| Dec 9, 2025 | Citigroup | Tyler Radke | Neutral | Maintains | $31.00 |
| Dec 9, 2025 | RBC Capital | Matthew Hedberg | Sector Perform | Downgrade | $31.00 |
| Dec 9, 2025 | DA Davidson | Rudy Kessinger | Neutral | Downgrade | $31.00 |
| Dec 8, 2025 | William Blair | Jason Ader | Market Perform | Downgrade | $N/A |
| Dec 8, 2025 | Wells Fargo | Ryan Macwilliams | Equal-Weight | Downgrade | $31.00 |
| Dec 8, 2025 | DA Davidson | Rudy Kessinger | Buy | Maintains | $29.00 |
| Oct 29, 2025 | Canaccord Genuity | Kingsley Crane | Buy | Maintains | $27.00 |
| Oct 28, 2025 | Stifel | Brad Reback | Hold | Maintains | $25.00 |
| Oct 28, 2025 | Piper Sandler | Rob Owens | Overweight | Maintains | $28.00 |
| Oct 28, 2025 | Truist Securities | Miller Jump | Buy | Maintains | $29.00 |
| Oct 28, 2025 | Goldman Sachs | Kash Rangan | Neutral | Maintains | $24.00 |
Confluent, Inc. Class A Common Stock (CFLT) Competitors
The following stocks are similar to Confluent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Confluent, Inc. Class A Common Stock (CFLT) Financial Data
Confluent, Inc. Class A Common Stock has a market capitalization of $11.13B with a P/E ratio of -36.0x. The company generates $1.17B in trailing twelve-month revenue with a -25.3% profit margin.
Revenue growth is +20.5% quarter-over-quarter, while maintaining an operating margin of -27.5% and return on equity of -27.7%.
Valuation Metrics
Market Cap
$11.13B
Enterprise Value
$10.13B
P/E Ratio
-36.0x
PEG Ratio
2.4x
Price/Sales
9.5x
Growth & Margins
Revenue Growth (YoY)
+20.5%
Gross Margin
+74.7%
Operating Margin
-27.5%
Net Margin
-25.3%
EPS Growth
+20.5%
Financial Health
Cash/Price Ratio
+18.5%
Current Ratio
3.8x
Debt/Equity
94.5x
ROE
-27.7%
ROA
-8.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Confluent, Inc. Class A Common Stock (CFLT) Business Model
About Confluent, Inc. Class A Common Stock
What They Do
Provides data streaming platforms for real-time data.
Business Model
The company operates on a subscription-based model, offering various cloud-native and on-premises solutions for data streaming. It generates revenue through its managed services like Confluent Cloud, self-managed enterprise platforms, and tailored solutions for regulated industries, catering to a wide range of sectors such as banking, retail, and telecommunications.
Additional Information
Founded in 2014 and headquartered in Mountain View, California, Confluent focuses on modernizing data infrastructure for event-driven applications and AI workloads. Its key offerings also include advanced analytics and AI integrations, positioning it as a critical player in the evolving data landscape.
Company Information
Sector
Technology
Industry
Software - Infrastructure
Employees
3,241
CEO
Mr. Edward Jay Kreps
Country
United States
IPO Year
2021
Website
www.confluent.ioConfluent, Inc. Class A Common Stock (CFLT) Latest News & Analysis
Latest News
Confluent Health Launches The Pain Perspective, Revealing a New National Portrait of Chronic Pain in America
23 days ago
Quick Summary
Confluent Health reports that the U.S. healthcare system may not be effectively addressing chronic pain, impacting millions of Americans in various aspects of life.
Why It Matters
Persistent chronic pain affects workforce productivity and healthcare costs, potentially impacting sectors like health insurance and pharmaceuticals, influencing investment strategies and market outlooks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Confluent, an IBM Company, has launched updates to Confluent Intelligence and Confluent Cloud, enhancing real-time AI application development and security by integrating Apache Flink pipelines.
Why It Matters
Confluent's advancements in AI application development and security enhance its competitive edge, potentially driving higher adoption rates and revenue growth, influencing investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Confluent Medical Technologies appointed Tom Testa as Chief Operating Officer, effective April 29, 2026, to enhance its leadership in medical device manufacturing.
Why It Matters
Tom Testa's appointment as COO may signal strategic shifts or operational improvements at Confluent, potentially impacting production efficiency and future profitability, influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Confluent, Inc. – CFLT
2 months ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Confluent, Inc. (NASDAQ: CFLT). Investors can contact Danielle Peyton for more information.
Why It Matters
The investigation into Confluent, Inc. by Pomerantz LLP may indicate potential legal issues or financial concerns, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Confluent, Inc. - CFLT
2 months ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Confluent, Inc. (NASDAQ: CFLT). Interested parties can contact Danielle Peyton for more information.
Why It Matters
The investigation into Confluent, Inc. may indicate potential legal risks or issues affecting the company's stock, impacting investor confidence and share prices.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IBM is set to report Q1 results on April 22, expected to meet forecasts. Bank of America adjusted estimates due to the early closing of the Confluent acquisition, predicting $50 million in revenue.
Why It Matters
IBM's upcoming earnings report aligns with forecasts, and the early Confluent acquisition may boost revenue. Adjusted estimates could impact stock performance and investor sentiment.
Source: Proactive Investors
Market Sentiment:
Positive
Frequently Asked Questions About CFLT Stock
What is Confluent, Inc. Class A Common Stock's (CFLT) stock forecast for 2027?
Based on our analysis of 43 Wall Street analysts, Confluent, Inc. Class A Common Stock (CFLT) has a median price target of $31.00. The highest price target is $31.00 and the lowest is $31.00.
Is CFLT stock a good investment in 2027?
According to current analyst ratings, CFLT has 0 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $30.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CFLT stock?
Wall Street analysts predict CFLT stock could reach $31.00 in the next 12 months. This represents a 0.0% increase from the current price of $30.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Confluent, Inc. Class A Common Stock's business model?
The company operates on a subscription-based model, offering various cloud-native and on-premises solutions for data streaming. It generates revenue through its managed services like Confluent Cloud, self-managed enterprise platforms, and tailored solutions for regulated industries, catering to a wide range of sectors such as banking, retail, and telecommunications.
What is the highest forecasted price for CFLT Confluent, Inc. Class A Common Stock?
The highest price target for CFLT is $31.00 from Peter Weed at Bernstein, which represents a 0.0% increase from the current price of $30.99.
What is the lowest forecasted price for CFLT Confluent, Inc. Class A Common Stock?
The lowest price target for CFLT is $31.00 from Peter Weed at Bernstein, which represents a 0.0% increase from the current price of $30.99.
What is the overall CFLT consensus from analysts for Confluent, Inc. Class A Common Stock?
The overall analyst consensus for CFLT is neutral. Out of 43 Wall Street analysts, 0 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $31.00.
How accurate are CFLT stock price projections?
Stock price projections, including those for Confluent, Inc. Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 2:58 AM UTC